ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "monocytes and systemic lupus erythematosus (SLE)"

  • Abstract Number: 2643 • ACR/ARHP Annual Meeting 2017

    HO-1 Expression in Monocytes Might Regulate Kidney Damage in Lupus Nephritis Patients

    Loreto Cuitino1,2, Javiera Obreque1,2, Patricia Gajardo-Meneses1,2, Gonzalo P. Méndez2,3, Alexis M. Kalergis2,4 and Carolina Llanos1,2, 1Departamento de Inmunología Clínica y Reumatología, Santiago, Chile, 2Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, 3Departamento de Anatomía Patológica, Santiago, Chile, 4Millennium Institute on Immunology and Immunotherapy and Departamento de Endocrinología, Santiago, Chile

    Background/Purpose: It is well established that up to 70% of systemic lupus erythematosus (SLE) patients will develop Lupus Nephritis (LN). Recent studies have revealed that…
  • Abstract Number: 2087 • ACR/ARHP Annual Meeting 2016

    A Type I Interferon Signature in Monocytes and Decreased Levels of Circulating Plasmacytoid Dendritic Cells in Patients with Primary Antiphospholipid Syndrome

    Lucas L. van den Hoogen1, Ruth D.E. Fritsch-Stork2, Marjan A. Versnel3, Ronald H.W.M. Derksen4, Joel A.G. van Roon5,6 and Timothy R.D.J. Radstake5,6, 1Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Immunology, Erasmus Medical Center, Rotterdam, Netherlands, 4Departments of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 5Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, 6Department of Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands

    Background/Purpose: In several autoimmune diseases, most notably in systemic lupus erythematosus (SLE), a type I interferon (IFN) signature has been described. This signature is thought…
  • Abstract Number: 210 • ACR/ARHP Annual Meeting 2015

    Phenotypically Divergences of Monocyte Subsets and Microparticles in Systemic Lupus Erythematosus Patients

    Catalina Burbano1, Gloria Vásquez2, Mauricio Rojas3 and Diana Castano4, 1Corporación Ciencias Básicas Biomédicas, Grupo de Inmunología celular e Inmunogenética, Universidad de Antioquia. Medellín, Antioquia, Colombia., Medellin, Colombia, 2Rheumatology, Universidad de Antioquia, Medellin, Colombia, 3Unidad de Citometría de Flujo, Universidad de Antioquia. Medellín, Antioquia, Colombia., Medellin, Colombia, 4Grupo Inmunología Celular e Inmunogenética, Universidad de Antioquia, Medellín, Colombia

    Background/Purpose: Mononuclear phagocytes depurate apoptotic cells, microparticles (MPs), and immune complexes (IC), leading to a tolerant or inflammatory microenvironment. The MPs, vesicular structures mainly produced…
  • Abstract Number: 729 • ACR/ARHP Annual Meeting 2015

    The Effect of Belimumab on Peripheral Blood Cells in Patients with Systemic Lupus Erythematosus

    Cosmin Dascalu1, Anne Davidson2, Meggan C. Mackay3, Richard Furie4, Weiqing Huang5 and Cynthia Aranow6, 1Medicine/Rheumatology, North Shore- Long Island Jewish, Manhasset, NY, 2Autoimmunity and Musculoskeletal Diseases, Feinstein Inst for Med Rsch, Manhasset, NY, 3Autoimmune & Musculoskeletal Disorders, The Feinstein Institute for Medical Research, Manhasset, NY, 4Division of Rheumatology, North Shore LIJ Health System, Lake Success, NY, 5Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, 6Feinstein Institute for Medical Research, Mahasset, NY

    Background/Purpose: The anti-BAFF antibody belimumab is the first biologic drug approved for treatment of mild-moderate SLE. While the efficacy of belimumab for this indication is…
  • Abstract Number: 1861 • ACR/ARHP Annual Meeting 2015

    Anti-Ds-DNA Antibodies Regulate Atherothrombosis in Systemic Lupus Erythematosus through the Induction of Netosis and the Prothrombotic and Proinflammatory Activities of Monocytes

    Carlos Perez-Sanchez1, M.Ángeles Aguirre Zamorano1, María Galindo2, Patricia Ruiz-Limon1, Nuria Barbarroja1, Yolanda Jiménez Gómez1, Pedro Segui3, Eduardo Collantes-Estevez1, Mª Jose Cuadrado4 and Chary Lopez-Pedrera1, 1IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, 2Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, 3IMIBIC-Reina Sofia University Hospital, Radiology Unit, Cordoba, Spain, 4Lupus Research Unit, St Thomas Hospital, London, United Kingdom

    Background/Purpose:  Atherothrombosis in systemic lupus erythematosus (SLE) has been related to the combined effects of autoimmune elements and cells of the immune system, where monocytes…
  • Abstract Number: 2694 • ACR/ARHP Annual Meeting 2014

    B Lymphocyte Stimulator (BLyS) Promotes Dysregulated Monocyte Function in Systemic Lupus Erythematosus(SLE)

    Eoghan M. McCarthy1, Joan Ní Gabhann2, Siobhán Smith2, Lorraine O' Neill3, Eamonn S. Molloy4, Donough Howard1, Paul G. O'Connell1, S. Donnelly5, Grainne M. Kearns6 and Caroline Jefferies2, 1Rheumatology, Beaumont Hospital, Dublin, Ireland, 2Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland, 3Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 4Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, 5Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, 6Rheumatology Department, Beaumont Hospital, Dublin, Ireland

    Background/Purpose SLE involves complex interactions between the innate and adaptive immune systems. Monocytes are increasingly recognised to play a key role in the dysregulated immune…
  • Abstract Number: 1617 • ACR/ARHP Annual Meeting 2014

    Single Cell Interferon Signatures in Lupus Patient Monocytes Reveal a Differential Impact of Interferon Signaling Between Monocyte Subtypes

    Zhongbo Jin1, Mark A. Jensen2, Jessica M. Dorschner1, Danielle Vsetecka1, Shreyasee Amin3, Ashima Makol4, Floranne C. Ernste5, Thomas Osborn6, Kevin G. Moder4, Vaidehi Chowdhary3 and Timothy B. Niewold1, 1Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 2Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 3Division of Rheumatology, Mayo Clinic, Rochester, MN, 4Rheumatology, Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, 6Dept of Rheumatology, Mayo Clinc, Rochester, MN

    Background/Purpose Type I interferon (IFN) is a primary pathogenic factor in human systemic lupus erythematosus (SLE).  IFN gene expression signatures have been observed in whole blood and mixed peripheral…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology